How AI Can Help Reduce Vaccine R&D From A Year To ‘A Matter Of Weeks’

From rapidly identifying antigenic targets to automating clinical trials, AI has an important role to play in cutting vaccine development time down to 100 days, says Melanie Saville, executive director of R&D at CEPI.

Virus AI

The Coalition for Epidemic Preparedness Innovations (CEPI) has pledged to facilitate the development of new vaccines within 100 days of a new pathogen with epidemic or pandemic potential being identified, but meeting this ambitious timeline will require significantly faster processes.

To deliver on its “100-Days Mission,” an initiative backed by G7 and G20 nations and first proposed in June 2021, CEPI has entered four international partnerships that will focus specifically on using

Key Takeaways
  • AI could help researchers to identify antigens for known viruses and create a library of virtual antigen designs, reducing early research timelines from a year or more to just weeks.

  • The use of AI in other drug and vaccine R&D settings, such as clinical trials, is also being explored

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

More from Geography